Highlights
KLSE: ADVENTA (7191)       ADVENTA BHD MAIN : Health Care
Last Price Today's Change   Day's Range   Trading Volume
1.52   -0.03 (1.94%)  1.51 - 1.57  1,236,800
Trade this stock for as low as 0.05% brokerage. Find out more.

Financials


Market Cap: 232 Million

Market Cap 232 Million
NOSH 153 Million

Latest Audited Result:  31-Dec-2019

Latest Audited Result: 31-Dec-2019
Announcement Date 22-Jun-2020
Next Audited Result: 31-Dec-2020
Est. Ann. Date: 22-Jun-2021
Est. Ann. Due Date: 29-Jun-2021

Latest Quarter:  30-Sep-2020 [#3]

Latest Quarter: 30-Sep-2020 [#3]
Announcement Date 25-Nov-2020
Next Quarter: 31-Dec-2020
Est. Ann. Date: 27-Feb-2021
Est. Ann. Due Date: 01-Mar-2021
QoQ | YoY   -409.11%  |    -117.30%

Annual (Unaudited) ( EPS: 14.49, P/E: 10.49 )

Revenue | NP to SH 38,881  |  22,141
RPS | P/RPS 25.45 Cent  |  5.97
EPS | P/E | EY 14.49 Cent  |  10.49  |  9.53%
DPS | DY | Payout % 7.00 Cent  |  4.61%  |  48.30%
NAPS | P/NAPS 0.23  |  6.61
YoY   186.59%
NP Margin | ROE 56.33%  |  63.01%
F.Y. | Ann. Date 31-Dec-2019  |  27-Feb-2020

T4Q Result ( EPS: -5.88, P/E: -25.85 )

Revenue | NP to SH 86,155  |  -8,985
RPS | P/RPS 56.39 Cent  |  2.70
EPS | P/E | EY -5.88 Cent  |  -25.85  |  -3.87%
DPS | DY | Payout % 7.00 Cent  |  4.61%  |  - %
NAPS | P/NAPS 0.42  |  3.62
QoQ | YoY   -133.97%  |    -867.29%
NP Margin | ROE -10.84%  |  -14.00%
F.Y. | Ann. Date 30-Sep-2020  |  25-Nov-2020

Annualized Result ( EPS: -2.15, P/E: -63.54 )

Revenue | NP to SH 99,350  |  -3,654
RPS | P/RPS 65.03 Cent  |  2.34
EPS | P/E | EY -2.15 Cent  |  -63.54  |  -1.57%
DPS | DY | Payout % -
NAPS | P/NAPS -
QoQ | YoY   -167.70%  |    -109.58%
NP Margin | ROE -3.68%  |  -5.70%
F.Y. | Ann. Date 30-Sep-2020  |  25-Nov-2020


Hints :
Click the QoQ or YoY on table to view the QoQ or YoY Financial Result page.

Click here to modify the Visible Columns.

Date Financial Result Financial Ratio Per Share Item Performance Valuation (End of Quarter) Valuation (Ann. Date)
F.Y. Ann. Date Quarter # Revenue PBT NP NP to SH Div Net Worth Div Payout % NP Margin ROE NOSH RPS Adj. RPS EPS Adj. EPS DPS Adj. DPS NAPS Adj. NAPS QoQ YoY EOQ Date EOQ Price EOQ P/RPS EOQ P/EPS EOQ P/NAPS EOQ EY EOQ DY ANN Date ANN Price ANN P/RPS ANN P/EPS ANN P/NAPS ANN EY ANN DY
31-Dec-2020 25-Nov-2020 30-Sep-2020 3 99,350 -3,654 -3,654 -3,654 - 64,170 - % -3.68% -5.70% 152,786 65.03 65.03 -2.15 -2.15 0.00 0.00 0.4200 0.42   -167.70%   -109.58% 30-Sep-2020 2.16 3.32 -90.30 5.14 -1.11% 0.00% 25-Nov-2020 2.09 3.21 -87.37 4.98 -1.14% 0.00%
31-Dec-2020 26-Aug-2020 30-Jun-2020 2 120,094 4,974 4,974 5,398 - 70,281 - % 4.14% 7.68% 152,786 78.60 78.60 3.54 3.54 0.00 0.00 0.4600 0.46   33.88%   267.33% 30-Jun-2020 1.51 1.92 42.74 3.28 2.34% 0.00% 26-Aug-2020 2.95 3.75 83.50 6.41 1.20% 0.00%
31-Dec-2020 21-May-2020 31-Mar-2020 1 54,696 3,632 3,584 4,032 - 67,225 - % 6.55% 6.00% 152,786 35.80 35.80 2.64 2.64 0.00 0.00 0.4400 0.44   -81.79%   182.02% 31-Mar-2020 0.505 1.41 19.14 1.15 5.23% 0.00% 21-May-2020 1.07 2.99 40.55 2.43 2.47% 0.00%
31-Dec-2019 27-Feb-2020 31-Dec-2019 4 38,881 23,304 21,901 22,141 10,695 35,140 48.30% 56.33% 63.01% 152,786 25.45 25.45 14.49 14.49 7.00 7.00 0.2300 0.23   -41.93%   186.59% 31-Dec-2019 0.60 2.36 4.14 2.61 24.15% 11.67% 27-Feb-2020 0.64 2.51 4.42 2.78 22.64% 10.94%
31-Dec-2019 26-Nov-2019 30-Sep-2019 3 36,318 39,148 38,005 38,130 - 82,504 - % 104.64% 46.22% 152,786 23.77 23.77 24.96 24.96 0.00 0.00 0.5400 0.54   1,281.98%   - % 30-Sep-2019 0.505 2.12 2.02 0.94 49.42% 0.00% 26-Nov-2019 0.53 2.23 2.12 0.98 47.09% 0.00%
31-Dec-2019 29-Aug-2019 30-Jun-2019 2 35,434 -142 -3,226 -3,226 - 53,475 - % -9.10% -6.03% 152,786 23.19 23.19 -2.12 -2.12 0.00 0.00 0.3500 0.35   34.38%   - % 28-Jun-2019 0.40 1.72 -18.94 1.14 -5.28% 0.00% 29-Aug-2019 0.535 2.31 -25.34 1.53 -3.95% 0.00%
31-Dec-2019 30-May-2019 31-Mar-2019 1 33,944 -1,740 -4,916 -4,916 - 53,475 - % -14.48% -9.19% 152,786 22.22 22.22 -3.20 -3.20 0.00 0.00 0.3500 0.35   80.77%   - % 29-Mar-2019 0.355 1.60 -11.03 1.01 -9.06% 0.00% 30-May-2019 0.405 1.82 -12.59 1.16 -7.94% 0.00%
31-Dec-2018 28-Feb-2019 31-Dec-2018 4 60,030 -23,190 -25,569 -25,569 - 55,002 - % -42.59% -46.49% 152,786 39.29 39.29 -16.74 -16.74 0.00 0.00 0.3600 0.36   -1,598.61%   - % 31-Dec-2018 0.435 1.11 -2.60 1.21 -38.47% 0.00% 28-Feb-2019 0.365 0.93 -2.18 1.01 -45.85% 0.00%
31-Dec-2018 26-Dec-2018 31-Oct-2018 57,007 3,896 1,706 1,706 - 82,504 - % 2.99% 2.07% 152,786 37.31 37.31 1.11 1.11 0.00 0.00 0.5400 0.54   - %   1,118.70% 31-Oct-2018 0.40 1.07 35.82 0.74 2.79% 0.00% 26-Dec-2018 0.39 1.05 34.92 0.72 2.86% 0.00%
31-Dec-2018 30-Sep-2018 3 0 0 0 0 - - - % - % - % 152,786 - - 0.00 0.00 0.00 0.00 - -   - %   - % 28-Sep-2018 0.435 0.00 0.00 0.00 0.00% 0.00% 0.00 0.00 0.00 0.00 0.00% 0.00%
31-Oct-2018 28-Sep-2018 31-Jul-2018 3 56,890 5,573 2,844 2,844 - 82,504 - % 5.00% 3.45% 152,786 37.24 37.24 1.87 1.87 0.00 0.00 0.5400 0.54   - %   474.93% 31-Jul-2018 0.525 1.41 28.20 0.97 3.55% 0.00% 28-Sep-2018 0.435 1.17 23.37 0.81 4.28% 0.00%
31-Dec-2018 30-Jun-2018 2 0 0 0 0 - - - % - % - % 152,786 - - 0.00 0.00 0.00 0.00 - -   - %   - % 29-Jun-2018 0.57 0.00 0.00 0.00 0.00% 0.00% 0.00 0.00 0.00 0.00 0.00% 0.00%
31-Oct-2018 20-Jun-2018 30-Apr-2018 2 58,496 5,614 2,752 2,752 - 82,504 - % 4.70% 3.34% 152,786 38.29 38.29 1.80 1.80 0.00 0.00 0.5400 0.54   - %   308.31% 30-Apr-2018 0.58 1.51 32.20 1.07 3.11% 0.00% 20-Jun-2018 0.575 1.50 31.92 1.06 3.13% 0.00%
31-Dec-2018 31-Mar-2018 1 0 0 0 0 - - - % - % - % 152,786 - - 0.00 0.00 0.00 0.00 - -   - %   - % 30-Mar-2018 0.585 0.00 0.00 0.00 0.00% 0.00% 0.00 0.00 0.00 0.00 0.00% 0.00%
31-Oct-2018 28-Mar-2018 31-Jan-2018 1 55,552 5,964 2,696 2,696 - 82,504 - % 4.85% 3.27% 152,786 36.36 36.36 1.76 1.76 0.00 0.00 0.5400 0.54   - %   252.88% 30-Jan-2018 0.59 1.62 33.44 1.09 2.99% 0.00% 28-Mar-2018 0.53 1.46 30.04 0.98 3.33% 0.00%
31-Dec-2017 31-Dec-2017 0 0 0 0 - 80,976 - % - % - % 152,786 - - 0.00 0.00 0.00 0.00 0.5300 0.53   - %   - % 29-Dec-2017 0.60 0.00 0.00 1.13 0.00% 0.00% 0.00 0.00 0.00 0.00 0.00% 0.00%
31-Oct-2017 29-Dec-2017 31-Oct-2017 44,236 1,528 140 140 - 80,976 - % 0.32% 0.17% 152,786 28.95 28.95 0.09 0.09 0.00 0.00 0.5300 0.53   -71.70%   -79.53% 31-Oct-2017 0.655 2.26 714.82 1.24 0.14% 0.00% 29-Dec-2017 0.60 2.07 654.80 1.13 0.15% 0.00%
31-Oct-2017 19-Sep-2017 31-Jul-2017 3 42,774 1,574 494 494 - 80,976 - % 1.16% 0.61% 152,786 28.00 28.00 0.32 0.32 0.00 0.00 0.5300 0.53   -26.61%   -29.87% 31-Jul-2017 0.68 2.43 210.03 1.28 0.48% 0.00% 19-Sep-2017 0.69 2.46 213.12 1.30 0.47% 0.00%
31-Oct-2017 22-Jun-2017 30-Apr-2017 2 43,122 1,446 674 674 - 80,976 - % 1.56% 0.83% 152,786 28.22 28.22 0.44 0.44 0.00 0.00 0.5300 0.53   -11.78%   -65.79% 28-Apr-2017 0.70 2.48 158.68 1.32 0.63% 0.00% 22-Jun-2017 0.72 2.55 163.21 1.36 0.61% 0.00%
31-Oct-2017 28-Mar-2017 31-Jan-2017 1 37,524 156 764 764 - 80,976 - % 2.04% 0.94% 152,786 24.56 24.56 0.52 0.52 0.00 0.00 0.5300 0.53   11.70%   -79.64% 31-Jan-2017 0.665 2.71 132.99 1.25 0.75% 0.00% 28-Mar-2017 0.68 2.77 135.99 1.28 0.74% 0.00%
31-Oct-2016 27-Dec-2016 31-Oct-2016 4 39,931 2,398 684 684 - 80,976 - % 1.71% 0.84% 152,786 26.14 26.14 0.45 0.45 0.00 0.00 0.5300 0.53   -3.02%   -77.86% 31-Oct-2016 0.78 2.98 174.23 1.47 0.57% 0.00% 27-Dec-2016 0.68 2.60 151.89 1.28 0.66% 0.00%
31-Oct-2016 29-Sep-2016 31-Jul-2016 3 39,150 2,130 705 705 - 80,257 - % 1.80% 0.88% 151,428 25.85 25.62 0.47 0.46 0.00 0.00 0.5300 0.53   -64.20%   -77.33% 29-Jul-2016 0.70 2.71 150.28 1.32 0.67% 0.00% 29-Sep-2016 0.73 2.82 156.72 1.38 0.64% 0.00%
31-Oct-2016 28-Jun-2016 30-Apr-2016 2 43,372 3,408 1,970 1,970 - 80,976 - % 4.54% 2.43% 152,786 28.39 28.39 1.28 1.28 0.00 0.00 0.5300 0.53   -47.49%   -35.03% 29-Apr-2016 0.84 2.96 65.15 1.58 1.53% 0.00% 28-Jun-2016 0.70 2.47 54.29 1.32 1.84% 0.00%
31-Oct-2016 29-Mar-2016 31-Jan-2016 1 49,212 5,432 3,752 3,752 - 80,976 - % 7.62% 4.63% 152,786 32.21 32.21 2.44 2.44 0.00 0.00 0.5300 0.53   21.46%   21.19% 29-Jan-2016 0.92 2.86 37.46 1.74 2.67% 0.00% 29-Mar-2016 0.88 2.73 35.83 1.66 2.79% 0.00%
31-Oct-2015 18-Dec-2015 31-Oct-2015 4 41,881 5,000 3,089 3,089 - 80,976 - % 7.38% 3.81% 152,786 27.41 27.41 2.02 2.02 0.00 0.00 0.5300 0.53   -0.70%   -30.80% 30-Oct-2015 0.97 3.54 47.98 1.83 2.08% 0.00% 18-Dec-2015 1.00 3.65 49.46 1.89 2.02% 0.00%
31-Oct-2015 22-Sep-2015 31-Jul-2015 3 42,445 5,161 3,110 3,110 - 79,448 - % 7.33% 3.92% 152,786 27.78 27.78 2.04 2.04 0.00 0.00 0.5200 0.52   2.59%   -26.24% 31-Jul-2015 1.00 3.60 49.12 1.92 2.04% 0.00% 22-Sep-2015 0.935 3.37 45.92 1.80 2.18% 0.00%
31-Oct-2015 23-Jun-2015 30-Apr-2015 2 44,794 5,286 3,032 3,032 - 79,448 - % 6.77% 3.82% 152,786 29.32 29.32 1.98 1.98 0.00 0.00 0.5200 0.52   -2.07%   -15.87% 30-Apr-2015 0.91 3.10 45.86 1.75 2.18% 0.00% 23-Jun-2015 1.02 3.48 51.40 1.96 1.95% 0.00%
31-Oct-2015 17-Mar-2015 31-Jan-2015 1 44,636 5,752 3,096 3,096 - 77,920 - % 6.94% 3.97% 152,786 29.21 29.21 2.04 2.04 0.00 0.00 0.5100 0.51   -30.65%   -44.83% 30-Jan-2015 0.86 2.94 42.44 1.69 2.36% 0.00% 17-Mar-2015 0.91 3.11 44.91 1.78 2.23% 0.00%
31-Oct-2014 23-Dec-2014 31-Oct-2014 4 34,797 6,647 4,464 4,464 - 78,031 - % 12.83% 5.72% 153,003 22.74 22.77 2.92 2.92 0.00 0.00 0.5100 0.51   5.85%   -94.58% 31-Oct-2014 0.96 4.22 32.90 1.88 3.04% 0.00% 23-Dec-2014 0.81 3.56 27.76 1.59 3.60% 0.00%
31-Oct-2014 25-Sep-2014 31-Jul-2014 3 30,796 6,196 4,217 4,217 - 76,393 - % 13.69% 5.52% 152,786 20.16 20.16 2.76 2.76 0.00 0.00 0.5000 0.50   17.02%   -98.42% 31-Jul-2014 1.04 5.16 37.68 2.08 2.65% 0.00% 25-Sep-2014 1.03 5.11 37.31 2.06 2.68% 0.00%
31-Oct-2014 25-Jun-2014 30-Apr-2014 2 26,012 5,394 3,604 3,604 - 74,865 - % 13.86% 4.81% 152,786 17.03 17.03 2.36 2.36 0.00 0.00 0.4900 0.49   -35.78%   -99.10% 30-Apr-2014 1.12 6.58 47.48 2.29 2.11% 0.00% 25-Jun-2014 1.13 6.64 47.90 2.31 2.09% 0.00%
31-Oct-2014 25-Mar-2014 31-Jan-2014 1 28,420 7,472 5,612 5,612 - 74,865 - % 19.75% 7.50% 152,786 18.60 18.60 3.68 3.68 0.00 0.00 0.4900 0.49   -93.19%   -99.29% 30-Jan-2014 1.01 5.43 27.50 2.06 3.64% 0.00% 25-Mar-2014 1.14 6.13 31.04 2.33 3.22% 0.00%
31-Oct-2013 23-Dec-2013 31-Oct-2013 4 27,376 83,034 82,418 82,423 - 73,332 - % 301.06% 112.40% 152,776 17.92 17.92 53.95 53.95 0.00 0.00 0.4800 0.48   -69.20%   222.70% 31-Oct-2013 1.00 5.58 1.85 2.08 53.95% 0.00% 23-Dec-2013 1.06 5.92 1.96 2.21 50.90% 0.00%
31-Oct-2013 26-Sep-2013 31-Jul-2013 3 28,934 267,298 267,576 267,576 - 65,697 - % 924.76% 407.28% 152,786 18.94 18.94 175.13 175.13 0.00 0.00 0.4300 0.43   -32.89%   1,332.11% 31-Jul-2013 0.745 3.93 0.43 1.73 235.08% 0.00% 26-Sep-2013 1.02 5.39 0.58 2.37 171.70% 0.00%
31-Oct-2013 27-Jun-2013 30-Apr-2013 2 28,860 396,806 398,708 398,708 - 91,670 - % 1,381.52% 434.94% 152,784 18.89 18.89 260.96 260.96 0.00 0.00 0.6000 0.60   -49.58%   2,150.81% 30-Apr-2013 0.40 2.12 0.15 0.67 652.40% 0.00% 27-Jun-2013 0.48 2.54 0.18 0.80 543.67% 0.00%
31-Oct-2013 27-Mar-2013 31-Jan-2013 1 14,212 785,432 790,776 790,776 - 90,143 - % 5,564.14% 877.24% 152,786 9.30 9.30 517.56 517.56 0.00 0.00 0.5900 0.59   2,995.98%   7,192.29% 31-Jan-2013 0.27 2.90 0.05 0.46 1,916.93% 0.00% 27-Mar-2013 0.32 3.44 0.06 0.54 1,617.41% 0.00%
31-Oct-2012 26-Dec-2012 31-Oct-2012 4 14,193 2,180 25,496 25,542 - 238,381 - % 179.64% 10.71% 152,808 9.29 9.29 16.72 16.72 0.00 0.00 1.5600 1.56   36.71%   510.32% 31-Oct-2012 1.90 20.46 11.37 1.22 8.80% 0.00% 26-Dec-2012 1.94 20.89 11.61 1.24 8.62% 0.00%
31-Oct-2012 24-Sep-2012 31-Jul-2012 3 12,517 -1,198 18,566 18,684 - 229,220 - % 148.33% 8.15% 152,813 8.19 8.19 12.23 12.23 0.00 0.00 1.5000 1.50   5.48%   10.72% 31-Jul-2012 1.90 23.20 15.54 1.27 6.44% 0.00% 24-Sep-2012 1.80 21.97 14.72 1.20 6.79% 0.00%
31-Oct-2012 28-Jun-2012 30-Apr-2012 2 11,534 -940 17,494 17,714 - 221,424 - % 151.67% 8.00% 152,706 7.55 7.55 11.60 11.59 0.00 0.00 1.4500 1.45   63.35%   2.52% 30-Apr-2012 1.43 18.93 12.33 0.99 8.11% 0.00% 28-Jun-2012 1.45 19.20 12.50 1.00 8.00% 0.00%
31-Oct-2012 26-Mar-2012 31-Jan-2012 1 10,280 -2,232 10,076 10,844 - 217,492 - % 98.02% 4.99% 153,163 6.71 6.73 7.08 7.10 0.00 0.00 1.4200 1.42   159.12%   -33.06% 31-Jan-2012 1.64 24.43 23.16 1.15 4.32% 0.00% 26-Mar-2012 1.53 22.80 21.61 1.08 4.63% 0.00%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.


NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ Δ & YoY Δ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.


Analyze this stock with MQ Trader system
  5 people like this.
 
sasword 传说中的肾亏股,令你亏钱亏到肾亏,卖肾然后逼你使用它们的洗肾机,榨干榨净你。
02/12/2020 11:47 AM
questra Sell. Doesnt do glove, home dialysis business bad. Next QR probably worse.
02/12/2020 3:29 PM
sasword After london biscuit and khee san faking qr and money laundering , this "act很大" will become the next member of fake qr and money laundering.
03/12/2020 12:14 AM
sasword No worry for those still get trapped, answer is given to you guys, by the end of year the price will be <1.0, happy keeping and suffering.
03/12/2020 9:52 AM
JohnFarmer458 downtrend stock. Protect your capital , move to uptrend healthcare stock like Comfort,Careplus,Ruberex,Supermax,Topglove
03/12/2020 11:22 AM
MaBadri Buy low
03/12/2020 10:36 PM
sasword Then sell lower.
04/12/2020 10:04 AM
sasword And gg just like syndicate dog "on my way to hexx"
04/12/2020 11:27 AM
questra Slowly going back to 50 sen
04/12/2020 2:00 PM
kok_wai1985 Adventa below RM0.50 soon.
04/12/2020 4:46 PM
wallstreetrookie The worst healthcare counter. Been calling since August. Shell company. Profit generated from selling subsidiaries.
05/12/2020 11:48 AM
sasword No profit, all fake qr.
07/12/2020 10:16 AM
sasword 这股不是泄死,而是已经巨人观了。
07/12/2020 4:06 PM
Taeyeon09 Buy careplus, going have huge rebound soon, next month qr out, huge profit increase
08/12/2020 12:15 AM
genghis when u thot this stock going to die.it went up
08/12/2020 10:13 AM
topglove123 Rebound!!! Buy now before fly!!!!!
08/12/2020 3:18 PM
sasword 回光返照,明天继续一泻万里。
08/12/2020 3:30 PM
topglove123 Engine start now to fly!!!!!!
08/12/2020 4:31 PM
Sinoboy Almost lu :)
08/12/2020 4:52 PM
MaBadri Rm4.00
08/12/2020 5:55 PM
ngothyeaun Lai Lai Lai...
08/12/2020 6:54 PM
kens88 Wow. Is the bull back. Even adventa fly
08/12/2020 9:28 PM
EngineeringProfit Unbelievable......

.....how violent

like the bear maw
08/12/2020 9:30 PM
NPRA1985 UAE says Sinopharm vaccine has 86% efficacy against COVID-19

DUBAI (Reuters) - An experimental coronavirus vaccine developed by China’s Sinopharm has 86% efficacy against the virus, the United Arab Emirates health ministry said on Wednesday, citing an interim analysis of a human trial underway there.

The Gulf Arab state in July started Phase 3 clinical trials of the vaccine, developed by Beijing Institute of Biological Product, a unit of Sinopharm’s China National Biotec Group (CNBG). In September, the UAE approved its emergency use for certain groups.

The analysis also shows “99% seroconversion rate of neutralizing antibody and 100% effectiveness in preventing moderate and severe cases of the disease”, the ministry said in a statement carried by the state news agency.

“The analysis shows no serious safety concerns,” it said.

It also said it had officially registered the vaccine, without elaborating, and that 31,000 volunteers across 125 nationalities participated in the UAE trial.

https://www.reuters.com/article/health-coronavirus-emirates/update-1-uae-says-sinopharm-vaccine-has-86-efficacy-against-covid-19-idUSL1N2IP09V
09/12/2020 3:37 PM
sasword 50 cents lai lai lai.
09/12/2020 4:32 PM
NPRA1985 United Arab Emirates Claims China’s Sinopharm Vaccine Is 100% Effective At Preventing Moderate And Severe Covid-19

TOPLINE The experimental vaccine developed by China National Pharmaceutical Group, also known as Sinopharm, is 86% effective at preventing Covid-19 infection and 100% effective at preventing severe and moderate disease, health officials from the United Arab Emirates announced Wednesday, although with scarce detail provided about the trial.

The UAE health ministry cited an interim analysis of a late-stage clinical trial involving 31,000 volunteers as the source of its information, though neither they nor Sinopharm provided any data from the trial to validate the claims such as how many participants were infected or how many actually received the vaccine.

The ministry said “no serious safety concerns” were observed, though, again, no information on side effects was provided.

The ministry said the announcement is a “significant vote of confidence by the UAE’s health authorities in the safety and efficacy of this vaccine.”

The ministry added that it had officially registered the vaccine at the request of the manufacturer, which it says could eventually lead to the shot’s widespread authorization.

https://www.forbes.com/sites/roberthart/2020/12/09/united-arab-emirates-claims-chinas-sinopharm-vaccine-is-100-effective-at-preventing-moderate-and-severe-covid-19/?sh=2a60fb42595c
09/12/2020 10:39 PM
NPRA1985 Hong Kong’s Ming Pao daily said in its editorial that there were grounds to believe that the UAE must have been stringent with the review and registration of the Chinese vaccine, given the country’s record of being transparent in its anti-virus policymaking and mass testing.

“The UAE also maintains sound ties with the West so sourcing vaccines from the United States or elsewhere should not be a grave challenge. If the Chinese vaccine is not safe or effective, there is no reason for the UAE to endorse Beijing’s vaccine propaganda and risk its own image and the health of its own people.

“Thus the UAE’s approval and its top leader’s injection of the SinoPharm vaccine have come as a much-needed vote of confidence that will help convince more countries. Diversified supply of vaccines, with viable alternatives from China, is key to ensuring fair and equitable access by poor countries,” said the op-ed.

SinoPharm revealed that senior officials in Egypt and Bahrain also took part in trials held there.

https://asiatimes.com/2020/12/uae-gives-chinese-vaccines-a-shot-in-the-arm/
11/12/2020 12:03 AM
roshazli Fact box: When and which Covid-19 vaccines are likely to be available in Asia

BEIJING/TOKYO/SEOUL/MANILA/TAIPEI/JAKARTA/DHAKA/HANOI (Dec 11): Trial data from Pfizer Inc with partner BioNTech SE, Moderna Inc and AstraZeneca Plc has shown their experimental vaccines are effective in preventing novel coronavirus infection.
While regulatory processes are underway, few Asian countries expect to receive significant amounts of the vaccines initially. Here are estimated distribution time lines, supply deals announced and clinical trials being held in the region.

Australia
The country has secured around 140 million doses: 53.8 million from AstraZeneca, 51 million from Novavax Inc, 10 million from Pfizer, and 25.5 million from distribution programme COVAX.
It expects delivery of 3.8 million doses of AstraZeneca's vaccine in January and February next year and plans to begin inoculations in March.

China
China has not announced supply deals with Western drugmakers, which instead have partnered with private companies in the country.AstraZeneca's vaccine may be approved in China by mid-2021 and its Chinese partner Shenzhen Kangtai Biological Products Co Ltd plans annual production capacity of at least 100 million doses by the end of this year.
For the Pfizer/BioNTech vaccine, a unit of Shanghai Fosun Pharmaceutical Group Co Ltd plans a Phase II trial.
Tibet Rhodiola Pharmaceutical Holding Co is bringing in Russian vaccine candidate Sputnik V and plans early and mid-stage trials in China.
China has also approved three vaccine candidates developed by Sinovac Biotech Ltd and state-owned China National Pharmaceutical Group (Sinopharm) for emergency use, and Sinopharm hopes its two candidates will get conditional approval for general use this year.

Japan
Japan has deals to buy 120 million doses from Pfizer/BioNTech in the first half of next year and 120 million from AstraZeneca - the first 30 million of which will be shipped by March 2021 - and 250 million from Novavax.
It is also in talks with Johnson & Johnson and has a deal with Shionogi & Co Ltd.
Experts said vaccine makers would need to conduct at least Phase I and II trials in Japan before seeking approval for use.

South Korea
The country has deals to buy 20 million doses each from AstraZeneca, Pfizer and Moderna and another 4 million doses from Johnson & Johnson's Janssen, enough to cover up to 34 million people.It will procure additional doses for 10 million people through COVAX.Inoculation is likely to start in the second quarter of next year to allow time to observe possible side effects.

India
The head of the Serum Institute of India, which makes the AstraZeneca vaccine, said on Nov. 23 the positive late-state trial result of the candidate will allow it to seek emergency use approval by year-end, before securing approval for full introduction by February or March.
India also expects a government-backed vaccine to be launched as early as February. It is also conducting a late-stage trial of Sputnik V.

Taiwan
Taiwan aims to secure around 15 million doses initially, both via the COVAX scheme and by direct purchases from manufacturers, and may buy an additional 15 million doses.
The government has said it hopes to begin vaccinations in the first quarter next year.

Malaysia
The Southeast Asian nation has agreed to buy 12.8 million doses of the Pfizer vaccine, becoming the first country in the region to announce a deal with the U.S. drugmaker after some expressed reservations over the need for the ultra-cold storage that the vaccine requires.
Pfizer will deliver the first batch of 1 million doses in the first quarter of next year.

The Philippines
The archipelago announced a deal on Nov. 27 for 2.6 million doses of the AstraZeneca vaccine and is discussing a possible 1 million more, covering about 1% of a population of 108 million people.It is also seeking 20 million to 50 million doses from Sinovac and is in talks with others, including Pfizer.Vaccine makers can seek approval from Philippine regulators even if no clinical trial is conducted in the country.

Indonesia
Southeast Asia's most populous country has secured 125.5 million doses from Sinovac, 30 million from Novavax, is in talks with AstraZeneca and Pfizer to buy 50 million doses each, and expects to get 16 million from COVAX.Indonesia is testing Sinovac's vaccine and preparing mass vaccination for medical staff and other frontline workers to start as soon as late January.

Vietnam
A government official said COVAX vaccines would cover only 20% of the population and the country is likely to have a chance to secure separate deals soon, as demand is very high.

Bangladesh
Bangladesh signed a deal with India's Serum Institute to buy 30 million doses of the AstraZeneca vaccine.It also expects to receive 68 million doses from global vaccine alliance GAVI at a subsidised rate, a senior health ministry official said.
11/12/2020 4:39 PM
sasword Ok sorry, 20 cents lai lai mari mari.
11/12/2020 5:03 PM
NPRA1985 Pfizer Vaccine Cleared in U.S., a Landmark in Covid-19 Fight

Pfizer Inc. gained emergency U.S. authorization for its Covid-19 vaccine on Friday, completing an unprecedented scientific sprint that could eventually help bring an end to a pandemic that has killed nearly 300,000 Americans

https://www.bloomberg.com/news/articles/2020-12-12/pfizer-covid-vaccine-wins-u-s-fda-emergency-use-authorization
12/12/2020 5:27 PM
NPRA1985 Bahrain Approves China’s Sinopharm Covid-19 Vaccine

Bahrain approved the registration of the Sinopharm Group Co Ltd. vaccine against the coronavirus, about a week after the United Arab Emirates registered the Chinese-made vaccine.

“Results from Phase III clinical trials showed an 86% efficacy rate, a 99% seroconversion rate of neutralizing antibody and 100% effectiveness in preventing moderate and severe cases of Covid-19,” the National Health Regulatory Authority said in a statement Sunday.

Bahrain has participated in phase III clinical trials, in which more than 7,700 volunteers signed up. Bahrain had previously authorized the emergency use of the vaccine, which was provided to frontline workers in contact with coronavirus patients.

The UAE registered the Sinopharm vaccine after finding it had a 86% efficacy rate, paving the way for a full public use and allowing for a re-opening of the Gulf nation’s economy.

Egypt plans to start the process of inoculation against the coronavirus after receiving the first shipments of Sinopharm vaccine.

https://www.bloomberg.com/news/articles/2020-12-13/bahrain-approves-china-s-sinopharm-covid-19-vaccine

https://abcnews.go.com/Health/wireStory/bahrain-approves-chinese-covid-19-vaccine-74699175
13/12/2020 5:55 PM
NPRA1985 Govt to increase Covid-19 vaccine purchase to cover 60%-70% of M'sians — PM

The government has plans to increase its purchase of the Covid-19 vaccine to cover the immunisation needs of about 60%-70% of Malaysians compared with 30% currently.

Prime Minister Tan Sri Muhyiddin Yassin said this was because some nations had purchased doses exceeding their population.

“As for Malaysia, we have already got 30%. I have instructed Health Minister Datuk Seri Dr Adham Baba along with [Science, Technology and Innovation Minister] Khairy Jamaluddin Abu Bakar to negotiate and increase it from 30% to 60% or 70%.

https://www.theedgemarkets.com/article/govt-mulls-increasing-covid19-vaccine-purchase-30-6070-meet-msians-immunisation-needs-%E2%80%94-pm
13/12/2020 6:22 PM
NPRA1985 COVID-19 vaccine is permissible for Muslim use, preservation of life is key consideration: MUIS

SINGAPORE: The Islamic Religious Council of Singapore (MUIS) said on Sunday (Dec 13) that it "holds the position that a COVID-19 vaccine is permissible for Muslim use".

"We would advise and encourage Muslims to be vaccinated once it is available and when the vaccine has been medically authorised as safe and effective, as this is a basic necessity to protect lives in the context of a global pandemic," said MUIS.

The council made its religious position on the vaccine known in a media release.

It said that the objectives of introducing a COVID-19 vaccine and the processes involved in producing vaccines are "largely aligned to established Islamic principles and values".

Islamic jurisprudence places great importance on the sanctity and safety of human life and the protection of livelihoods, it said.

Efforts to protect human life from any form of danger and harm, such as the development of vaccines, are therefore highly encouraged in Islam, it added.

https://www.channelnewsasia.com/news/singapore/covid-19-vaccine-muis-permissible-for-muslim-use-halal-13762806
13/12/2020 8:24 PM
sasword That's right, show us the power of 10 cents mari mari lai lai lai.
14/12/2020 9:35 AM
topglove123 Now still cheap faster buy!!!!
31/12/2020 3:03 PM
sasword Now damn "cheap", faster all in. later "shoot up" to 0.10 do not say bojio.
06/01/2021 5:11 PM
sasword Now big shark and rotten gov pakat money laundering in share market, next week sure drop below 1.50
08/01/2021 5:13 PM
MaBadri Kejar
09/01/2021 8:23 AM
Invicibletrader MCO 2.0 is coming, COVID-19 cases consistently above 2000+, if you are smart, you should know where to put the money over next few weeks.
10/01/2021 10:22 PM
STEADYBOMBIBI85 https://www.thestar.com.my/business/business-news/2021/01/11/all-4-big-glove-stocks-offer-plenty-of-upside-kenanga
11/01/2021 6:13 PM
SiLiaw triple confirm gloves counter is game over even with mco announcement it is not fly
12/01/2021 9:44 AM
ooi8888 si liaw loh, cannot escape, how? buy high sell low?
13/01/2021 10:16 PM
Genghis Run...
13/01/2021 11:15 PM
freddiehero how can it be.
13/01/2021 11:19 PM
ooi8888 because si liaw loh
14/01/2021 10:09 AM
Yang Addison otw to rm1???
19/01/2021 6:56 PM
KLLee_0110 Shortage of hospital beds due to covid 19 business should be ok
22/01/2021 9:31 AM
KLLee_0110 Today hope to be the best top gainers counter long time did not break the best top
22/01/2021 9:33 AM
Nathan27 Quite a slow mover
22/01/2021 12:29 PM
learner1234 The worst glove counter..no hope i guess.
22/01/2021 2:10 PM